On May 17, 2022, BBS-Bioactive Bone Substitutes Plc (BBS) received information that the U.S. Patent and Trademark Office has provided a Note of Publication of BBS's new pending patent application.
“BBS has filed this supplementary application to maximize the coverage of its patents. This application, which supplements our prior patents, relates to certain materials used to prepare ARTEBONE® products and to methods of using the product for medical treatment. The authorities did not approve a minor part of the claims of the previously approved patent (published on 11 January 2022), and with this new application the company will continue to defend these claims”, says Ilkka Kangasniemi, CEO of BBS.
The authorities have published the application in order to inform the public about its existence, and the publication of the application may grant the BBS certain temporary rights.
For more information:
Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: firstname.lastname@example.org